Joseph Anderson

Partner

2020 - Current

Board Director

2009

F2G Ltd Aug 2022 - present Autolus Therapeutics Feb 2016 - present Algeta ASA 2009 - 2013 (acquired by Bayer) Amarin plc 2009 - 2013 Epigenomics Ag 2012 - 2014 Cytos Biotechnology Ag 2012 - 2016 (Merged with Kuros Bioscience AG)

Arix Bioscience plc, Cofounder, CEO and CIO

2016 - 2020

Partner

2004 - 2015

Partner at Abingworth, a leading life science investment firm with offices in the UK, California and Boston. Led investments in US and EU life science and healthcare companies, taking board seats where relevant and an active role in developing the businesses. Established and led the successful VIPE practice (venture investing in public equities). Also founded and co-managed Abingworth's public equities hedge fund with a 10 year track record of success.

Head of Global Healthcare Equities and Portfolio Manager

1999 - 2003

Led a team of analysts generating healthcare stock ideas for global equities portfolios across First State Group. Founded and managed the S&P A-rated Global Health and Biotechnology Fund.

Pharmaceuticals Analyst

1998 - 1999

Sell-side analyst responsible for European Pharmaceutical coverage. In depth thematic research notes as well as company specific reports and recommendations.

Head of Strategy Group

1990 - 1998

Led the strategy and policy research team, supporting the Board in developing strategy and promoting medical science globally. Member of the Wellcome Trust Management Committee.

Head of Research

1985 - 1989

Consultancy team specialising in analysis and advice on medical research and the healthcare industry for internal and external clients